MARKET

QURE

QURE

Uniqure
NASDAQ
26.15
+0.50
+1.95%
Opening 11:56 02/09 EST
OPEN
25.54
PREV CLOSE
25.65
HIGH
26.38
LOW
25.01
VOLUME
566.20K
TURNOVER
--
52 WEEK HIGH
71.50
52 WEEK LOW
7.76
MARKET CAP
1.63B
P/E (TTM)
-5.9632
1D
5D
1M
3M
1Y
5Y
1D
How Early AMT-191 Gene Therapy Signals Will Impact uniQure (QURE) Investors
Simply Wall St · 14h ago
Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch
Benzinga · 3d ago
Balanced Risk/Reward at uniQure: Early Promise for AMT-191 Offset by Regulatory and Competitive Uncertainty Around AMT-130
TipRanks · 3d ago
uniQure Shares Updated AMT-191 Phase I/IIa Results With Sustained α-Gal A Expression Over One Year And Six Of 11 Patients Discontinuing Enzyme Replacement Therapy
Benzinga · 3d ago
uniQure announces preliminary AMT-191 Phase I/IIa data
TipRanks · 3d ago
A Look At uniQure (QURE) Valuation After FDA Setback And Legal Investigations
Simply Wall St · 6d ago
Weekly Report: what happened at QURE last week (0126-0130)?
Weekly Report · 02/02 10:00
uniQure (QURE) Is Down 9.4% After FDA Deems AMT-130 Data Insufficient for BLA Filing
Simply Wall St · 02/01 22:20
More
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Webull offers Uniqure NV stock information, including NASDAQ: QURE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QURE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QURE stock methods without spending real money on the virtual paper trading platform.